Osteoporosis - Inflammatory effects on bone metabolism and fracture risk;Osteoporose - inflammatorische Effekte auf den Knochenstoffwechsel und das Frakturrisiko

Zeitschrift fur Orthopadie und Unfallchirurgie

Volumn 152, Issue 2, 2014, Pages 170-176

  Dischereit, G ^a   Lange, U ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

bone metabolism; fracture risk; osteoporosis; proinflammatory cytokines

Indexed keywords

CYTOKINE; IMMUNOLOGIC FACTOR;

BIOLOGICAL MODEL; BONE; FRACTURE; FRAGILITY FRACTURE; HUMAN; IMMUNOLOGY; OSTEITIS; RISK FACTOR;

BONE AND BONES; CYTOKINES; FRACTURES, BONE; HUMANS; IMMUNOLOGIC FACTORS; MODELS, IMMUNOLOGICAL; OSTEITIS; OSTEOPOROTIC FRACTURES; RISK FACTORS;

EID: 84899571364     PISSN: 18646697     EISSN: 18646743     Source Type: Journal    
DOI: 10.1055/s-0034-1368247     Document Type: Article

References (50)

1. Goldring S. R. Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int: 2003; 73 97 100 (Pubitemid 37082354)
2. Sinigaglia L., Varenna M., Girasole G. et al. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am: 2006; 32 631 658
3. Clowes J. A., Riggs B. L., Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev: 2005; 208 207 227 (Pubitemid 41746395)
4. Riggs B. L., Khosla S., Melton L. J. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev: 2002; 23 279 302 (Pubitemid 34651948)
5. Jilka R. L. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone: 1998; 23 75 81 (Pubitemid 28379866)
6. Hofbauer L. C., Khosla S., Dunstan C. R. et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res: 2000; 15 2 12 (Pubitemid 30026926)
7. Hofbauer L. C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA: 2004; 292 490 495 (Pubitemid 38988958)
8. Hofbauer L. C. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). Ann Endocrinol (Paris): 2006; 67 139 141
9. Braun T., Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther: 2011; 13 235
10. Hwang S., Putney J. W. Orai1-mediated calcium entry plays a critical role in osteoclast differentiation and function by regulating activation of the transcription factor NFATc1. FASEB J: 2012; 26 1484 1492
11. Neumann E., Schett G. Knochenstoffwechsel. Molekulare Mechanismen. Z Rheumatol: 2007; 66 286 289
12. Moon S., Ahn I. E., Jung H. et al. Temporal differential effects of proinflammatory cytokines on osteoclastogenesis. Int J Mol Med: 2013; 31 769 777
13. Nakamura I., Takahashi N., Jimi E. et al. Regulation of osteoclast function. Mod Rheumatol: 2012; 22 167 177
14. Visvanathan S., van der Heijde D., Deodhar A. et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis: 2009; 68 175 182
15. Jagger C. J., Lean J. M., Davies J. T. et al. Tumor necrosis factor-alpha mediates osteopenia caused by depletion of antioxidants. Endocrinology: 2005; 146 113 118 (Pubitemid 40051730)
16. Lean J. M., Davies J. T., Fuller K. et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest: 2003; 112 915 923 (Pubitemid 38063749)
17. Lean J. M., Jagger C. J., Kirstein B. et al. Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology: 2005; 146 728 735 (Pubitemid 40129828)
18. Abrahamsen B., Bonnevie-Nielsen V., Ebbesen E. N. et al. Cytokines and bone loss in a 5-year longitudinal study-hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res: 2000; 15 1545 1554 (Pubitemid 30484524)
19. Hustmyer F. G., Walker E., Yu X. P. et al. Cytokine production and surface antigen expression by peripheral blood mononuclear cells in postmenopausal osteoporosis. J Bone Miner Res: 1993; 8 51 59 (Pubitemid 23033996)
20. Pacifici R., Vannice J. L., Rifas L. et al. Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. J Clin Endocrinol Metab: 1993; 77 1135 1141 (Pubitemid 23345458)
21. Bismar H., Diel I., Ziegler R. et al. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab: 1995; 80 3351 3355
22. Scheidt-Nave C., Bismar H., Leidig-Bruckner G. et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab: 2001; 86 2032 2042 (Pubitemid 32472916)
23. Romas E., Martin T. J. Cytokines in the pathogenesis of osteoporosis. Osteoporos Int: 1997; 7 03 S47 S53
24. Chao T., Yu H., Huang C. et al. Association of interleukin-1 beta (- 511C/T) polymorphisms with osteoporosis in postmenopausal women. Ann Saudi Med: 2010; 30 437 441
25. Jabbar S., Drury J., Fordham J. N. et al. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosi. J Clin Pathol: 2011; 64 354 357
26. Pacifici R., Rifas L., Teitelbaum S. et al. Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc Natl Acad Sci U S A: 1987; 84 4616 4620 (Pubitemid 17097860)
27. Zheng S. X., Vrindts Y., Lopez M. et al. Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas: 1997; 26 63 71 (Pubitemid 27063783)
28. Khosla S., Peterson J. M., Egan K. et al. Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab: 1994; 79 707 711 (Pubitemid 24286389)
29. Zarrabeitia M. T., Riancho J. A., Amado J. A. et al. Cytokine production by peripheral blood cells in postmenopausal osteoporosis. Bone Miner: 1991; 14 161 167
30. Papadopoulos N. G., Georganas K., Skoutellas V. et al. Correlation of interleukin-6 serum levels with bone density in postmenopausal women. Clin Rheumatol: 1997; 16 162 165 (Pubitemid 27119788)
31. Giuliani N., Sansoni P., Girasole G. et al. Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes. Exp Gerontol: 2001; 36 547 557 (Pubitemid 32201509)
32. Tamura T., Udagawa N., Takahashi N. et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A: 1993; 90 11924 11928 (Pubitemid 24008752)
33. Kania D. M., Binkley N., Checovich M. et al. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J Am Geriatr Soc: 1995; 43 236 239
34. McKane W. R., Khosla S., Peterson J. M. et al. Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. J Bone Mine Res: 1994; 9 1313 1318 (Pubitemid 24238362)
35. Ding C., Parameswaran V., Udayan R. et al. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab: 2008; 93 1952 1958 (Pubitemid 351656543)
36. Salamone L. M., Whiteside T., Friberg D. et al. Cytokine production and bone mineral density at the lumbar spine and femoral neck in premenopausal women. Calcif Tissue Int: 1998; 63 466 470 (Pubitemid 28531794)
37. Bouxsein M. L., Karasik D. Bone geometry and skeletal fragility. Curr Osteoporos Rep: 2006; 4 49 56 (Pubitemid 44623936)
38. Lauretani F., Bandinelli S., Russo C. R. et al. Correlates of bone quality in older persons. Bone: 2006; 39 915 921 (Pubitemid 44335881)
39. Russo C. R., Lauretani F., Seeman E. et al. Structural adaptations to bone loss in aging men and women. Bone: 2006; 38 112 118 (Pubitemid 43006081)
40. Barbour K. E., Boudreau R., Danielson M. E. et al. Inflammatory markers and the risk of hip fracture: The women's health initiative. J Bone Miner Res: 2012; 27 1167 1176
41. McLean R. R. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep: 2009; 7 134 139
42. Cauley J. A., Danielson M. E., Boudreau R. M. et al. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Mine Res: 2007; 22 1088 1095 (Pubitemid 351339731)
43. Aderka D., Engelmann H., Shemer-Avni Y. et al. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res: 1992; 11 157 159
44. Xing Z., Gauldie J., Cox G. et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J clin Invest: 1998; 101 311 320 (Pubitemid 28067327)
45. Ridker P. M., Hennekens C. H., Buring J. E. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med: 2000; 342 836 843 (Pubitemid 30165206)
46. Weinhold B., Rüther U. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. Biochem J: 1997; 327 Pt 2 425 429 (Pubitemid 27477818)
47. Koh J., Khang Y., Jung C. et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int: 2005; 16 1263 1271 (Pubitemid 41396955)
48. Kim B., Yu Y. M., Kim E. N. et al. Relationship between serum hsCRP concentration and biochemical bone turnover markers in healthy pre- and postmenopausal women. Clin Endocrinol (Oxf): 2007; 67 152 158 (Pubitemid 46957455)
49. Pasco J. A., Kotowicz M. A., Henry M. J. et al. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA: 2006; 296 1353 1355 (Pubitemid 44427419)
50. Schett G., Kiechl S., Weger S. et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med: 2006; 166 2495 2501 (Pubitemid 44913235)